Prostatic acid phosphatase (PAP) is an enzyme produced by the prostate. It may be found in increased amounts in men who have prostate cancer or other diseases. The highest levels of acid phosphatase are found in metastasized prostate cancer. Diseases of the bone, such as Paget?s disease or hyperparathyroidism, diseases of blood cells, such as sinkle-cell disease or multiple myeloma or lysosomal storage disease, such as Gaucher?s disease, will show moderately increased levels. Certain medications can cause temporary increases or decreases in acid phosphatase levels. Manipulation of the prostate gland through massage, biopsy or rectal exam before a test can increase the level.

PAP ELISA:

Immunoenzymatic colorimetric method (ELISA) for quantitative determination of PAP in serum or plasma

Principle of the Assay:

The PAP assay is based on simultaneous binding of human PAP to two monoclonal antibodies; one is immobilized on the microplate, the other is soluble and conjugated with horseradish peroxidase (HRP). Microtiter strip wells are precoated with anti-PAP IgG antibodies. PAP in samples and standards binds to the immobilised antibodies on the surface of the microtiter wells and the second, soluble anti-PAP antibody-enzyme conjugate binds to the immobile antibody-PAP-complex during the first incubation. Afterwards a bound/free separation is performed by solid-phase washing. The immune complex is visualized by adding Tetramethylbenzidine (TMB) substrate, which gives a blue reaction product. The intensity of this product is proportional to the amount of PAP in samples and standards. Sulphuric acid is added to stop the reaction. This produces a yellow endpoint colour. Absorption at 450 nm is read using an ELISA microwell plate reader.

Specific performance characteristics:

Order information: